FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044337871> ?p ?o ?g. }

• W2044337871 endingPage "187" @default.
• W2044337871 startingPage "181" @default.
• W2044337871 abstract "The authors have previously reported that in elderly patients treated with low doses of perphenazine, few extrapyramidal symptoms (EPS) developed in those who were not poor CYP2D6 metabolizers. The authors hypothesized that this atypical side effect profile is due to perphenazine's principal metabolite, n-dealkylperphenazine (DAPZ), which is usually present in vivo at concentrations 1.5 to 2 times that of the parent drug. Perphenazine, DAPZ, and 7-hydroxyperphenazine affinities were examined in vitro by competition-binding analysis to isolated human receptors expressed in transfected cell lines. Perphenazine and metabolite effects were examined in vivo in 54 older patients who were treated with perphenazine, at a target dose of 0.1 mg/kg, for 10 to 17 days. Drug concentrations were determined by high-performance liquid chromatography with electrochemical detection. In in vitro binding studies, DAPZ demonstrated a higher affinity for serotonin-2A receptors than for dopamine-2 receptors to an extent comparable to that of some atypical neuroleptic agents. In contrast, perphenazine and 7-hydroxyperphenazine demonstrated a higher affinity for dopamine-2 receptors than for serotonin-2A receptors. The mean +/- SD concentrations in the 54 subjects were the following: perphenazine, 1.5 +/- 1.4 ng/mL; DAPZ, 2.0 +/-1.6 ng/mL; and 7-hydroxyperphenazine, 0.8 +/- 1.9 ng/mL. The mean +/- SD quotient for the DAPZ/perphenazine concentration was 1.7 +/- 1.1 and for the 7-hydroxyperphenazine/perphenazine was 0.54 +/-1.6. EPS onset was not correlated with the perphenazine concentration, the metabolite concentrations, the DAPZ/perphenazine quotient, or the 7-hydroxyperphenazine/perphenazine quotient. Despite a moderately atypical receptor-binding profile, DAPZ does not seem to moderate perphenazine effects in vivo in older patients. This outcome likely reflects the low potency of DAPZ for dopamine-2 and serotonin-2A receptors relative to the potency of perphenazine for these receptors. Further exploration of atypical properties of DAPZ should include de novo administration of this metabolite in animal models." @default.
• W2044337871 created "2016-06-24" @default.
• W2044337871 creator A5000921316 @default.
• W2044337871 creator A5019562259 @default.
• W2044337871 creator A5025744036 @default.
• W2044337871 creator A5027721925 @default.
• W2044337871 creator A5030512910 @default.
• W2044337871 creator A5079952417 @default.
• W2044337871 creator A5088688660 @default.
• W2044337871 creator A5011904636 @default.
• W2044337871 date "2000-04-01" @default.
• W2044337871 modified "2023-09-24" @default.
• W2044337871 title "Pharmacologic Profile of Perphenazine's Metabolites" @default.
• W2044337871 cites W153750880 @default.
• W2044337871 cites W1966264743 @default.
• W2044337871 cites W1970551789 @default.
• W2044337871 cites W1976654631 @default.
• W2044337871 cites W1981805188 @default.
• W2044337871 cites W1986415396 @default.
• W2044337871 cites W1986450889 @default.
• W2044337871 cites W1991208077 @default.
• W2044337871 cites W2025972002 @default.
• W2044337871 cites W2031736446 @default.
• W2044337871 cites W2039727503 @default.
• W2044337871 cites W2065792595 @default.
• W2044337871 cites W2068316730 @default.
• W2044337871 cites W2081490257 @default.
• W2044337871 cites W2090641365 @default.
• W2044337871 cites W2126704418 @default.
• W2044337871 cites W2165379748 @default.
• W2044337871 cites W4232865890 @default.
• W2044337871 cites W4299533981 @default.
• W2044337871 cites W90819564 @default.
• W2044337871 doi "https://doi.org/10.1097/00004714-200004000-00010" @default.
• W2044337871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10770456" @default.
• W2044337871 hasPublicationYear "2000" @default.
• W2044337871 type Work @default.
• W2044337871 sameAs 2044337871 @default.
• W2044337871 citedByCount "30" @default.
• W2044337871 countsByYear W20443378712012 @default.
• W2044337871 countsByYear W20443378712015 @default.
• W2044337871 countsByYear W20443378712016 @default.
• W2044337871 countsByYear W20443378712017 @default.
• W2044337871 countsByYear W20443378712018 @default.
• W2044337871 countsByYear W20443378712019 @default.
• W2044337871 countsByYear W20443378712020 @default.
• W2044337871 countsByYear W20443378712021 @default.
• W2044337871 countsByYear W20443378712023 @default.
• W2044337871 crossrefType "journal-article" @default.
• W2044337871 hasAuthorship W2044337871A5000921316 @default.
• W2044337871 hasAuthorship W2044337871A5011904636 @default.
• W2044337871 hasAuthorship W2044337871A5019562259 @default.
• W2044337871 hasAuthorship W2044337871A5025744036 @default.
• W2044337871 hasAuthorship W2044337871A5027721925 @default.
• W2044337871 hasAuthorship W2044337871A5030512910 @default.
• W2044337871 hasAuthorship W2044337871A5079952417 @default.
• W2044337871 hasAuthorship W2044337871A5088688660 @default.
• W2044337871 hasConcept C126322002 @default.
• W2044337871 hasConcept C150903083 @default.
• W2044337871 hasConcept C170493617 @default.
• W2044337871 hasConcept C185592680 @default.
• W2044337871 hasConcept C207001950 @default.
• W2044337871 hasConcept C2775864247 @default.
• W2044337871 hasConcept C2776743534 @default.
• W2044337871 hasConcept C2777477808 @default.
• W2044337871 hasConcept C2780777758 @default.
• W2044337871 hasConcept C2780948584 @default.
• W2044337871 hasConcept C513476851 @default.
• W2044337871 hasConcept C53910766 @default.
• W2044337871 hasConcept C55493867 @default.
• W2044337871 hasConcept C71924100 @default.
• W2044337871 hasConcept C86803240 @default.
• W2044337871 hasConcept C98274493 @default.
• W2044337871 hasConceptScore W2044337871C126322002 @default.
• W2044337871 hasConceptScore W2044337871C150903083 @default.
• W2044337871 hasConceptScore W2044337871C170493617 @default.
• W2044337871 hasConceptScore W2044337871C185592680 @default.
• W2044337871 hasConceptScore W2044337871C207001950 @default.
• W2044337871 hasConceptScore W2044337871C2775864247 @default.
• W2044337871 hasConceptScore W2044337871C2776743534 @default.
• W2044337871 hasConceptScore W2044337871C2777477808 @default.
• W2044337871 hasConceptScore W2044337871C2780777758 @default.
• W2044337871 hasConceptScore W2044337871C2780948584 @default.
• W2044337871 hasConceptScore W2044337871C513476851 @default.
• W2044337871 hasConceptScore W2044337871C53910766 @default.
• W2044337871 hasConceptScore W2044337871C55493867 @default.
• W2044337871 hasConceptScore W2044337871C71924100 @default.
• W2044337871 hasConceptScore W2044337871C86803240 @default.
• W2044337871 hasConceptScore W2044337871C98274493 @default.
• W2044337871 hasIssue "2" @default.
• W2044337871 hasLocation W20443378711 @default.
• W2044337871 hasLocation W20443378712 @default.
• W2044337871 hasOpenAccess W2044337871 @default.
• W2044337871 hasPrimaryLocation W20443378711 @default.
• W2044337871 hasRelatedWork W1990128461 @default.
• W2044337871 hasRelatedWork W1991089708 @default.
• W2044337871 hasRelatedWork W2016684134 @default.
• W2044337871 hasRelatedWork W2055262758 @default.

• next